Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ATM I1294Nfs*8 ATM E2977Rfs*2 |
Therapy | Irinotecan + Olaparib |
Indication/Tumor Type | colorectal adenocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATM I1294Nfs*8 ATM E2977Rfs*2 | colorectal adenocarcinoma | predicted - sensitive | Irinotecan + Olaparib | Case Reports/Case Series | Actionable | In a clinical case study, Lynparza (olaparib) and Camptosar (irinotecan) combination treatment resulted in decreased tumor markers and stable disease in the primary and metastatic tumors in a heavily pretreated patient with metastatic colorectal adenocarcinoma harboring ATM E2977Rfs*2, ATM I1294Nfs*8, and KRAS G13D, lasting at least 4 months (PMID: 35004311). | 35004311 |
PubMed Id | Reference Title | Details |
---|---|---|
(35004311) | Case Report: Combination of Olaparib With Chemotherapy in a Patient With ATM-Deficient Colorectal Cancer. | Full reference... |